NuCana stock gained 2.83 percent on October 6 as patent coverage expands

Published on 10/07/2026 at 02:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

NuCana stock was last at USD 1.09 on October 6, 2026, after a 2.83 percent session gain. A European patent expands NUC-7738 protection beyond 85 issued patents.

NCNA, US67022C3043, Illustration mit AI erstellt.

NuCana stock (ISIN US67022C3043) was last at USD 1.09 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, up 2.83 percent from USD 1.06. The move followed a September 30 patent announcement that adds European protection for the company's lead cancer candidate NUC-7738.

Patent estate tops 85 issued patents

According to GlobeNewswire on September 30, 2026, the European Patent Office granted patent EP 3683225 covering the composition of matter of NUC-7738. NuCana said the candidate is now protected by over 85 issued patents worldwide, including earlier composition-of-matter patents in the United States and China.

The European grant strengthens the intellectual-property position around the program, but the development timeline remains central to the investment case. The candidate is being evaluated in the Phase 2 part of a Phase 1/2 study in combination with pembrolizumab for patients with PD-1 inhibitor-resistant metastatic melanoma, according to GlobeNewswire.

Cash runway reaches into 2029

NuCana said on September 30, 2026 that its cash resources are expected to fund planned operations into 2029. The statement gives the company a defined financing horizon while it works toward clinical milestones during the remainder of 2026, although it is a forward-looking company estimate rather than a reported revenue figure.

That distinction matters for NCNA because the latest operating story is centered on clinical progress and intellectual property. The European patent covers the chemical structure of NUC-7738, positioning the asset's protection alongside its ongoing clinical evaluation rather than creating a commercial sales milestone.

NCNA trades above its yearly low

NuCana's October 6 session ranged from USD 1.05 to USD 1.14 on Nasdaq, with volume of 50,937 shares. The USD 1.09 last price stood above the 52-week low of USD 0.95 and below the 52-week high of USD 7.22, while market capitalization was USD 6.6 million as of October 6, 2026.

For investors, the key checkpoint is whether the 2026 clinical milestones convert the patent estate into progress in the pipeline. The stock's 2.83 percent session gain gives the European patent announcement a measurable market response, while the wide 52-week range shows that development outcomes remain the larger valuation variable.

NuCana stock was last at USD 1.09

NuCana stock was last at USD 1.09 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, with the session's 2.83 percent gain and a market capitalization of USD 6.6 million.